P1.13-36 Randomized Phase 2 Trial of Seribantumab in Combination With Erlotinib in Patients With EGFR Wild-Type Non-Small Cell Lung Cancer

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.893
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Randomized Phase II Trial of Seribantumab in Combination With Erlotinib in Patients With EGFR Wild‐Type Non‐Small Cell Lung Cancer

Oncologist
Cancer ResearchMedicineOncology
2019English

A Phase II Trial of Erlotinib Monotherapy for Pretreated Elderly Patients With Advanced EGFR Wild-Type Non-Small Cell Lung Cancer

BMC Research Notes
BiochemistryMedicineGeneticsMolecular Biology
2015English

P3.01-37 Phase II Study of Amrubicin Plus Erlotinib in Previously Treated, Advanced Non-Small Cell Lung Cancer Patients With Wild-Type EGFR: TORG 1320

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Predictive Factors in Patients With EGFR Mutation‑negative Non‑small Cell Lung Cancer Treated With Erlotinib

Oncology Letters
Cancer ResearchOncology
2014English

Erlotinib Treatment in Pretreated Patients With Non-Small Cell Lung Cancer: A Phase II Study

Oncology Letters
Cancer ResearchOncology
2010English

Phase I Trial of Sorafenib in Combination With Gefitinib in Patients With Refractory or Recurrent Non Small Cell Lung Cancer

Clinical Cancer Research
Cancer ResearchOncology
2007English

Erlotinib Resistance With EGFR L858r/Y891d Double Mutation in a Patient With Non–Small Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2019English

Second-Line Erlotinib in an EGFR Mutation-Negative Patient With Non-Small-Cell Lung Cancer

Current Oncology
Oncology
2012English

Minocycline Reduces Chemoradiation-Related Symptom Burden in Patients With Non–small Cell Lung Cancer: A Phase II Randomized Trial

International Journal of Radiation Oncology Biology Physics
OncologyRadiologyCancer ResearchRadiationNuclear MedicineImaging
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy